Emcure Pharmaceuticals
EMCURENSE

Emcure Pharmaceuticals

₹2,020.1016.30 (0.81%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,998.10
Today’s high
2,045.00
52 week low
1,260.00
52 week high
2,100.70
Open price
2,045.00
Previous close
2,003.80
Live volume
1,07,539
Lower circuit
1,803.50
Upper circuit
2,204.10

Fundamentals

Market Cap
₹38,241Cr
ROE
18.67%
P/E Ratio(TTM)
37.53
EPS(TTM)
53.71
P/B Ratio
7.73
Dividend Yield
0.18%
Industry P/E
38.08
Book Value
260.93
Debt to Equity
0.31
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
JUN '26
₹2,583Cr
+4.40%
₹292Cr
+20.00%
07501.5k2.25k3k
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+23%
3Y CAGR+16%
Profit growthValue
1Y (TTM)+36%
3Y CAGR+19%

About

Emcure Pharmaceuticals Limited is a research-driven pharmaceutical company, developing and manufacturing affordable and innovative medicines across various therapeutic areas.;
CEO/MD
Satish Mehta
Founded in
1981
NSE symbol
EMCURE

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Abbott IndiaABBOTINDIA
₹27,095.00
-175.00 (0.64%)
L
    H
    57,955.7635.8912.14
    ₹2,016.50
    +6.90 (0.34%)
    L
      H
      51,019.9237.16.33
      ₹2,848.10
      +9.30 (0.33%)
      L
        H
        48,312.0645.2321.31
        ₹2,412.25
        0.00 (--)
        L
          H
          38,730.7754.599.31
          Livesquawk
          Emcure Pharma's Sanand plant in Gujarat gains US FDA approval for specific formulations.
          Livesquawk
          Jefferies reiterates Buy on Emcure Pharma with ₹2,320 target, citing strong 10% revenue and 12% EBITDA beats. Domestic growth recovered 10% YoY; international markets exceeded estimates by 8-24%, driving FY27-29 EPS upgrade by 6%.
          This stock has no events currently